Joseph E. Cruz, Pharm.D., BCPS
Joseph E. Cruz, Pharm.D., BCPS is Clinical Assistant Professor at Rutgers University, and The State University of New Jersey Clinical Coordinator - Internal Medicine Englewood Hospital and Medical Center.
Cardiac Matters
Cangrealor is the first FDA-approved P2Y12 inhibitor.
PCSK9 Inhibitors: The First of Their Kind
The first of their kind, evolocumab and alirocumab belong to a new class of cholesterol lowering agents.
New combo therapy for chronic heart failure
Entresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.